Iteos Home

Pipeline

Home / Pipeline

Cancer immunotherapies by design, and in development.

Our two clinical-stage product candidates, EOS-448 and Inupadenant, each target a key mechanism that inhibits an effective antitumor immune response: a novel checkpoint TIGIT and the ATP adenosine pathway, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.

More about our pipeline

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

EOS-448

+ dostarlimab | 1L NSCLC PDL1high

Phase 2, planned

+ dostarlimab | HNSCC

Phase 2, active

+ dostarlimab + CD96 | Advanced Malignancies

Phase 1, active

+ dostarlimab + Inupadenant | Advanced Malignancies

Phase 1, planned

+ Inupadenant | Advanced Malignancies

Phase 2, active

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

Phase 2, active

Inupadenant

Monotherapy | High Biomarker

Phase 2, active

+ pembrolizumab | PD-1 Resistant Melanoma

Phase 2, active

+ chemotherapy | 2L Chemo-naive NSCLC

Phase 2, active

EOS-984

IND Enabling Studies

Preclinical, active

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

Child kissing older woman on cheek.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.

We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.